Closed Solicitation · DEPARTMENT OF VETERANS AFFAIRS
AI Summary
The Department of Veterans Affairs intends to negotiate a sole source contract for the FDA approved radioactive therapy drug Lu177 PLUVICTO and Lu177 LUTATHERA. This unique product is essential for prostate cancer treatment and will be supplied by Novartis. The contract will be a one-year firm fixed price, and no competitive proposals will be solicited.
Notice of Intent to Sole Source Requirement The Department of Veterans Affairs, VA Healthcare System, Network 10 Contracting Office intends to negotiate a sole source contract for a FDA approved radioactive therapy drug under the authority of GSAR 538.7104-3(b)(1)(ii): Only one source is capable of providing the supplies or services required at the level of quality required because the supplies or services are unique or highly specialized. The associated NAICS code for this is 325412. The vendor will be Novartis, Route 10, East Hanover, NJ, 07936. Description of services: SUPPLY: This is a new FDA approved radioactive therapy drug. The therapeutic effectiveness of this radioactive drug has changed standard patient care guidelines and now patients diagnosed with prostate cancer are recommended to have Lu177 PLUVICTO as a treatment option. Also needed is the purchase of the Lu177 LUTATHERA. A One Year firm fixed price contract shall be awarded. It is the Government's belief that only the proposed candidate possesses the required capabilities to successfully meet this requirement. It is the Government's intention to solicit and negotiate with only this source. This notice of intent is not a request for competitive proposals. It is not a solicitation or request for offers.
6505--RADIOPHARMACEUTICALS PLUVICTO / LUTATHERA - NUCLEAR MED, IND is a federal acquisition solicitation issued by DEPARTMENT OF VETERANS AFFAIRS. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.
SamSearch Platform
AI-powered intelligence for the right opportunities, the right leads, and the right time.